XBiotech financials
$2.18+1.40%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $4.0M | $18.4M | $44.0M | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $3.4M | $12.6M | $9.4M | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | 83.8% | 68.4% | 21.5% | — | — | — | — |
| Operating income | -$55.7M | -$42.5M | -$37.5M | -$34.5M | -$25.1M | -$18.3M | -$31.2M | -$21.0M | -$34.1M | -$52.8M |
| Net income | -$45.5M | -$38.5M | -$24.6M | -$32.9M | -$17.4M | -$11.2M | $668.6M | -$21.1M | -$33.1M | -$52.8M |
| Net margin | — | — | — | −820.4% | −94.7% | −25.5% | — | — | — | — |
| Diluted EPS | $-1.49 | $-1.26 | $-0.81 | $-1.08 | $-0.58 | $-0.36 | $14.44 | $-0.59 | $-0.95 | $-1.63 |
| EBITDA | -$54.0M | -$40.7M | -$35.8M | -$31.9M | -$22.4M | -$16.0M | -$28.9M | -$18.6M | -$32.6M | -$52.1M |
| Operating cash flow | -$39.9M | -$31.0M | -$18.7M | -$14.8M | $69.4M | -$65.1M | -$18.3M | -$16.5M | -$33.6M | -$46.0M |
| Free cash flow | -$40.2M | -$32.3M | -$19.1M | -$15.4M | $65.9M | -$68.9M | -$18.5M | -$16.7M | -$35.1M | -$59.9M |
| Diluted shares | 30.5M | 30.5M | 30.4M | 30.4M | 30.0M | 30.8M | 46.3M | 35.8M | 34.9M | 32.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $125.6M | $172.7M | $200.0M | $157.3M | $237.0M | $237.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $60.2M | — | — |
| Total debt | $0.00 | $10.3M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $150.1M | $199.1M | $226.6M | $246.1M | $275.2M | $353.7M |
| Total liabilities | $9.7M | $16.8M | $7.8M | $5.7M | $5.8M | $5.1M |
| Shareholders' equity | $140.3M | $182.3M | $218.8M | $240.4M | $269.4M | $348.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology